Quality of Care Indicators for Gout Management

Arthritis and Rheumatism

Volumn 50, Issue 3, 2004, Pages 937-943

  Mikuls, Ted R ^a,g   MacLean, Catherine H ^b,c   Olivieri, Jason ^d   Patino, Fausto ^d   Allison, Jeroan J ^d   Farrar, John T ^e   Bilker, Warren B ^e   Saag, Kenneth G ^d,f  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RAND CORPORATION   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f FOT   (United States)

^g 983025 Nebraska Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIINFLAMMATORY AGENT; COLCHICINE; CORTICOTROPIN; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; BONE MARROW SUPPRESSION; COUNSELING; EVIDENCE BASED MEDICINE; GOUT; HEALTH CARE QUALITY; HUMAN; INTERNET; LIFESTYLE; MEDICAL PRACTICE; MYOPATHY; PATIENT CARE; PEPTIC ULCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; STANDARD; TOXICITY; UNITED STATES; VALIDATION PROCESS;

GOUT; HUMANS; QUALITY INDICATORS, HEALTH CARE;

EID: 1542313924     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20102     Document Type: Article

References (111)

1. Chin MH, Wang LC, Jin L, Mulliken R, Walter J, Hayley DC, et al. Appropriateness of medication selection for older persons in an urban academic emergency department. Acad Emerg Med 1999;6:1232-42.
2. Evans TI, Wheeler MT, Small RE, Breitbach SA, Sanders KM, Roberts WN. A comprehensive investigation of inpatient intravenous colchicine use shows more education is needed. J Rheumatol 1996;23:143-8.
3. McClintock AD, Egan AJ, Woods DJ, Pillans PI. A survey of allopurinol dosage prescribing. N Z Med J 1995;108:346-7.
4. Shekelle PG, MacLean CH, Morton SC, Wenger NS. Assessing care of vulnerable elders: methods for developing quality indicators. Ann Intern Med 2001;135(8 suppl 2):647-52.
5. Shekelle PG, Kahan JP, Bernstein SJ, Leape LL, Kamberg CJ, Park RE. The reproducibility of a method to identify the overuse and underuse of medical procedures. N Engl J Med 1998;338:1888-95.
6. Shekelle PG, Chassin MR, Park RE. Assessing the predictive validity of the RAND/UCLA appropriateness method criteria for performing carotid endarterectomy. Int J Technol Assess Health Care 1998;14:707-27.
7. Brook R. The RAND/UCLA appropriateness method. In: McCormick K, Moore S, Siegel R, editors. US Agency for Health Care Policy and Research Office of the Forum for Quality and Effectiveness in Health Care clinical practice guideline development: methodology perspectives. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research; 1994. p. 59-70.
8. Kravitz RL, Laouri M, Kahan JP, Guzy P, Sherman T, Hilborne L, et al. Validity of criteria used for detecting underuse of coronary revascularization. JAMA 1995;274:632-8.
9. Selby JV, Fireman BH, Lundstrom RJ, Swain BE, Truman AF, Wong CC, et al. Variation among hospitals in coronary-angiography practices and outcomes after myocardial infarction in a large health maintenance organization. N Engl J Med 1996;335:1888-96.
10. MacLean CH. Quality indicators for the management of osteoarthritis in vulnerable elders. Ann Intern Med 2001;135(8 Suppl 2):711-21.
11. Fonarow GC. Quality indicators for the management of heart failure in vulnerable elders. Ann Intern Med 200;135(8 Suppl 2):694-702.
12. Chow TW, MacLean CH. Quality indicators for dementia in vulnerable community-dwelling and hospitalized elders. Ann Intern Med 200;135(8 Suppl 2):668-76.
13. Grossman JM, MacLean CH. Quality indicators for the management of osteoporosis in vulnerable elders. Ann Intern Med 200;135(8 Suppl 2):722-30.
14. Bates-Jensen BM. Quality indicators for prevention and management of pressure ulcers in vulnerable elders. Ann Intern Med 200;135(8 Suppl 2):744-51.
15. Schnelle JF, Smith RL. Quality indicators for the management of urinary incontinence in vulnerable community-dwelling elders. Ann Intern Med 2001;135(8 Suppl 2):752-8.
16. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in gout. Aust N Z J Med 1987;17:301-4.
17. Paulus HE, Schlosstein LH, Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy of intercritical gout. Arthritis Rheum 1974;17:609-13.
18. Rosenfeld J. Effect of long-term allopurinol administration on serial GFR in normotensive and hypertensive subjects. Adv Exp Med Biol 1974;41:581-96.
19. Gibson T, Simmonds H, Potter C. Sequential studies of renal function in gout. Eur J Rheumatol Inflam 1979;3:79-90.
20. Gibson T, Simmonds H, Potter C, Rogers V. A controlled study of the effect of long term allopurinol treatment on renal function in gout. Adv Exp Med Biol 1980;122A:257-62.
21. Gibson T, Rodgers V, Potter C, Simmonds HA. Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis 1982;41:59-65.
22. Bull P, Scott J. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol 1989;16:1246-8.
23. Scott JT. Comparison of allopurinol and probenecid. Ann Rheum Dis 1966;25:623-6.
24. Walter-Sack I, de Vries JX, Ernst B, Frei M, Kolb S, Kosmowski J, et al. Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients: therapeutic equivalence to allopurinol. J Rheumatol 1996;23:498-501.
25. Normand S, McNeil B, Peterson L, Palmer R. Eliciting expert opinion using the Delphi technique: identifying performance indicators for cardiovascular disease. Int J Qual Health Care 1998;10:247-60.
26. Naylor CD, McGlynn EA, Leape LL, Pinfold SP, Bernstein SJ, Hilborne LH, et al, for the Canadian Revascularization Panel and the Canadian Coronary Angiography Panel. Coronary angiography and revascularization: defining procedural indications through formal group processes. Can J Cardiol 1994;10:41-8.
27. Schuster M, Asch S, McGlynn E, Kerr E, Hardy A, Gifford D. Development of a quality of care measurement system for children and adolescents: methodological considerations and comparisons with a system for adult women. Arch Pediatr Adolesc Med 1997;151:1085-92.
28. Ashton CM, Kuykendall DH, Johnson ML, Wun CC, Wray NP, Carr MJ, et al. A method of developing and weighting explicit process of care criteria for quality assessment. Med Care 1994;32:755-70.
29. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995;311:376-80.
30. Holloway R, Vickrey B, Benesch C, Hinchey J, Bieber J. Development of performance measures for acute ischemic stroke. Stroke 2001;32:2058-74.
31. Wallace S, Singer J. Systemic toxicity associated with intravenous administration of colchicine: guidelines for use. J Rheumatol 1988;15:495-9.
32. Hande K, Noone R, Stone W. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
33. Elion G, Yu T, Gutman A, Hitchings G. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med 1968;45:69-77.
34. Elion G, Benezra F, Beardmore T, Kelley W. Studies of allopurinol in patients with impaired renal function. Biol Med 1980;122A:263-7.
35. Aubock J, Fritsch P. Asymptomatic hyperuricemia and allopurinol-induced toxic epidermal necrolysis. BMJ 1985;290:1969-70.
36. Chan H, Ku G, Khoo O. Allopurinol associated hypersensitivity reactions: cutaneous and renal manifestations. Aust N Z J Med 1977;7:518-22.
37. Boyer T, Sun N, Reynolds T. Allopurinol hypersensitivity vasculitis and liver damage. West J Med 1977;126:143-7.
38. Lupton G, Odom R. The allopurinol hypersensitivity syndrome. J Am Acad Dermatol 1979;1:365-74.
39. Lindsey S, Evans E. Allopurinol hypersensitivity syndrome: effects and treatment. VA Med 1978;105:297-9.
40. Mills R. Severe hypersensitivity reactions associated with allopurinol. JAMA 1971;216:799-802.
41. McInnes G, Lawson D, Jick H. Acute adverse reactions attributed to allopurinol in hospitalized patients. Ann Rheum Dis 1981;40:245-9.
42. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986;29:82-7.
43. Young J, Boswell R, Nies A. Severe allopurinol hypersensitivity: association with thiazide and prior renal compromise. Arch Intern Med 1974;134:553-8.
44. Raman G, Sharman V, Lee H. Azathioprine and allopurinol: a potentially dangerous combination. J Intern Med 1990;228:69-71.
45. Zazgornik J, Kopsa H, Schmidt P, Pils P, Kuschan K, Deutsch E. Increased danger of bone marrow damage in simultaneous azathioprine-allopurinol therapy. Int J Clin Pharmacol Ther 1981;19:96-7.
46. Rundles R, Wyngaarden J, Hitchings G, Elion B, Silberman H. Effects of xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia, and gout. Trans Assoc Am Physicians 1963;76:126-40.
47. Jacobs F, Mamzer-Bruneel MF, Skhiri H, Thervet E, Legendre C, Kreis H. Safety of the mycophenolate mofetil-allopurinol combination in kidney transplant recipients with gout. Transplantation 1997;64:1087-8.
48. Braun W, Richmond B, Protiva D, Gifford R, Straffon R. The incidence and management of osteoporosis, gout, and avascular necrosis in recipients of renal allografts functioning more than 20 years (level 5A) treated with prednisone and azathioprine. Transplant Proc 1999;31:1366-9.
49. Sorenson LB, Levinson DJ. Clinical evaluation of benzbromarone: a new uricosuric drug. Arthritis Rheum 1976;19:183-90.
50. Persellin R, Schmid F. The use of sulfinpyrazone in the treatment of gout reduces uric acid level and diminishes severity of arthritic attacks with freedom from significant toxicity. JAMA 1961;175:971-5.
51. Rundles R, Elion G, Hitchings G. Allopurinol in the treatment of gout secondary to hyperuricemia. Bull Rheum Dis 1966;16:400-3.
52. Houpt JB. The effect of allpurinol (HPP) in the treatment of gout. Arthritis Rheum 1965;8:899-904.
53. Grahame R, Scott J. Clinical study of 354 patients with gout. Ann Rheum Dis 1970;29:461-8.
54. Klinenberg J, Goldfinger S, Seegmiller J. The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Ann Intern Med 1965;62:639-47.
55. Delbarre F, Amor B, Auscher C, deGery A. Treatment of gout with allopurinol: a study of 106 cases. Ann Rheum Dis 1966;25:627-33.
56. Wymgaarden J, Rundles R, Silberman H, Hunter S. Control of hyperuricemia with hydroxypyrazolopyrimidine, a purine analogue which inhibits uric acid synthesis. Arthritis Rheum 1963;6:306-7.
57. Yu T, Gutman A. Effect of allopurinol (4-hydroxypyrazole (3,4-d) pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am J Med 1964;37:639-47.
58. Wilson J, Simmonds H, North J. Allopurinol in the treatment of uraemic patients with gout. Ann Rheum Dis 1967;26:136-42.
59. Yu T. The effect of allopurinol in primary and secondary gout. Arthritis Rheum 1965;8:905-6.
60. Smyth CJ. Studies with allopurinol (HPP) in patients with tophaceous gout. Arthritis Rheum 1965;8:907-10.
61. Hollingworth P, Reardon J, Scott J. Acute gout during hypuricaemic therapy: prophylaxis with colchicine. Ann Rheum Dis 1980;39:529.
62. Fessel W. Renal outcomes of gout and hyperuricemia. Am J Med 1979;67:74-82.
63. Devlin J, Bellamy N, Bayliff C. Observations and effects of educational consults on allopurinol prescribing. Can J Hosp Pharm 1992;45:21-7.
64. Bluestone R, Klinenberg J, Lee I. Benzbromarone as a long-term uricosuric agent. Adv Exp Med Biol 1980;122A:283-6.
65. Briney WG, Ogden D, Bartholomew B, Smyth CJ. The influence of allopurinol on renal function in gout. Arthritis Rheum 1975;18:877-81.
66. Yu T. Pharmacokinetic and clinical studies of a new uricosuric agent: benzbromarone. J Rheumatol 1976;3:305-12.
67. Talbott J, Bishop C, Norcross B, Lockie L. The clinical and metabolic effects of benemid in patients with gout. Trans Assoc Am Physicians 1951;64:372-7.
68. DeGery A, Auscher C, Saporta L, Delbarre F. Treatment of gout and hyperuricemia by benzbromarone ethyl 2 (dibromo-3,5 hydroxy-4 benzoyl)-3 benzofuran. Adv Exp Med Biol 1974;41:683-9.
69. Brewis I, Ellis R, Scott J. Single daily dose of allopurinol. Ann Rheum Dis 1975;34:256-9.
70. Rodnan G, Robin J, Tolchin S, Elion G. Allopurinol and gouty hyperuricemia: efficacy of a single daily dose. JAMA 1975;231:1143-5.
71. McCarthy GM, Barthelemy CR, Veum JA, Wortmann RL. Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. Arthritis Rheum 1991;34:1489-94.
72. Hall A, Holloway V, Scott J. 4-hydroxypyazolo (3,4-d) pyrimidine in the treatment of gout: preliminary observations. Ann Rheum Dis 1964;23:439-46.
73. Loebl W, Scott J. Withdrawal of allopurinol in patients with gout. Ann Rheum Dis 1974;33:304-7.
74. Ferber H, Bader U, Matzkies F. The action of benzbromarone in relation to age, sex, and accompanying diseases. Adv Exp Med Biol 1980;122A:287-94.
75. Gaines LM Jr, Shulman LE. The failure of uricosuric drugs to reduce the attack rate in primary nontophaceous gout. Arthritis Rheum 1969;12:663-4.
76. Gutman A, Yu T. Protracted uricosuric therapy in tophaceous gout. Lancet 1957;2:1258-60.
77. Kuzell W, Seebach L, Glover R, Jackman A. Treatment of gout with allopurinol and sulphinpyrazone in combination and with allopurinol alone. Ann Rheum Dis 1966;25:634-42.
78. Day RO, Miners JO, Birkett DJ, Whitehead A, Naidoo D, Hayes J, et al. Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol 1988;26:423-8.
79. Peterson GM, Boyle RR, Francis HW, Oliver NW, Paterson J, von Witt RJ, et al. Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy. Eur J Clin Pharmacol 1990;39:419-21.
80. Ralston S, Capell H, Sturrock R. Alcohol and response to treatment of gout. BMJ 1988;296:1641-2.
81. Nicholls A, Scott J. Effect of weight loss on plasma and urinary levels of uric acid. Lancet 1972;2:1223-4.
82. Davis J, Bartfeld H. The effect of intravenous colchicine on acute gout. Am J Med 1954;16:218-9.
83. Davis J. Safety and effectiveness of colchicine by intravenous administration in the treatment of gout. J Clin Pharmacol 1969;9:410-2.
84. Carmichael L. Treatment of acute gout with injection of colchicine. JAMA 1959;170:1410-1.
85. Calabro J, Khoury M, Smyth C. Clinoril in acute gout. Acta Rheum Port 1974;8:163-6.
86. Emmerson B. Regimen of indomethacin therapy in acute gouty arthritis. BMJ 1967;2:272-4.
87. Boardman P, Hart F. Indomethacin in the treatment of acute gout. Practitioner 1965;194:560-5.
88. Schweitz M, Nashel D, Alepa F. Ibuprofen in the treatment of acute gouty arthritis. JAMA 1978;239:34-5.
89. Tausch G, Eberl R. Efficacy, tolerance and safety of piroxicam in the treatment of acute gout. Eur J Rheumatol Inflam 1978;1:365-8.
90. Widmark P. Safety and efficacy of piroxicam in the treatment of acute gout. Eur J Rheumatol Inflam 1978;1:346-8.
91. Murphy J. Piroxicam in the treatment of acute gout: a multicentre open study in general practice. J Intern Med Res 1979;7:507-10.
92. Karachalios G. Ibuprofen (brufen) treatment of acute gouty arthritis. Clin Trial J 1981;18:176-9.
93. Karachalios G. Treatment of gouty arthritis with piroxicam. Clin Exp Rheumatol 1985;3:63-5.
94. Kuzell W, Schaffarzick R, Brown B. Phenylbutazone (butazolidin) in rheumatoid arthritis and gout. JAMA 1952;149:729-34.
95. Cuq P. Treatment of acute attacks of gout with naproxen. Scand J Rheumatol 1973;Suppl 2:64-8.
96. Fletcher MA, Wade AG. Clinical experience with isoxicam in patients with acute gout. Br J Clin Pract 1985;39:108-13.
97. Marcolongo R, Lucchese M, Caruso I, Fuagalli M, Bruni G, Sacchetti G. IV indoprofen for prompt relief of acute gout. J Int Med Res 1980;8:326-32.
98. Willkens RF, Case JB, Huix FJ. The treatment of acute gout with naproxen. J Clin Pharmacol 1975;15:363-6.
99. Wanasukapunt S, Lertratanakul Y, Rubinstein HM. Effect of fenoprofen calcium on acute gouty arthritis. Arthritis Rheum 1976;19:933-5.
100. Altman R, Honig S, Levin J, Lightfoot R. Ketoprofen vs. indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988;15:1422-6.
101. Eberl R, Dunky A. Meclofenamate sodium in the treatment of acute gout: results of a double-blind study. Arzneimittel-Forschung 1993;33:641-3.
102. Fraser R, Howard D, Walker F. Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricemia. J Royal Col Gen Pract 1987;37:409-11.
103. Ruotsi A, Vainio U. Treatment of acute gouty arthritis with proquazone and indomethacin: a comparative, double-blind trial. Scand J Rheumatol 1978;21 Suppl:15-7.
104. Smyth C, Percy J. Comparison of indomethacin and phenylbutazone in acute gout. Practitioner 1973;32:351-3.
105. Sturge RA, Scott JT, Hamilton EB, Liyanage SP, Dixon AS, Davies J, et al. Multicentre trial of naproxen and phenylbutazone in acute gout. Ann Rheum Dis 1977;36:80-2.
106. Weiner GI, White SR, Weitzner RI, Rubinstein HM. Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis. Arthritis Rheum 1979;22:425-6.
107. Reardon J, Stockman A, Darlington L, Scott J. Double-blind trial of feprazone and phenylbutazone in acute gout. Curr Med Res Opin 1980;6:445-8.
108. Tumrasvin T, Deesomchok U. Piroxicam in the treatment of acute gout: high dose versus low dose. J Med Assoc Thai 1985;68:111-6.
109. Douglas G, Thompson M. Comparison of phenylbutazone and flufenamic acid in treatment of acute gout. Ann Phys Med 1970;10:275-80.
110. Butler RC, Goddard DH, Higgens CS, Hollingworth P, Pease CT, Stodell MA, et al. Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis. Br J Clin Pharmacol 1985;20:511-3.
111. Wallace S, Singer J, Duncan G, Wigley F, Kuncl R. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol 1991;18:264-9.